Mandate

Vinge represents Sidec Technologies in the issue of new shares

May 09, 2007

Vinge is representing Sidec Technologies, in conjunction with the investments by Industrifonden, Investor and Earlybird of Germany in the company. A capital infusion of SEK 68.5 million means that Sidec can implement its planned efforts on the European and American markets. The company, which was established in 2000, is a spin-off from research at the Karolinska Institute, and is engaged in technology developed for studies of protein.
 
Partner Johan Winnerbald and associate Anna Berntsson represent Sidec Technologies AB.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025